There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Black Diamond Therapeutics (BDTX), Sesen Bio (SESN) and Johnson & Johnson (JNJ) with bullish sentiments.
Black Diamond Therapeutics (BDTX)
In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on Black Diamond Therapeutics, with a price target of $58.00. The company’s shares closed last Monday at $24.20.
According to TipRanks.com, Shu is a 4-star analyst with an average return of 19.6% and a 73.7% success rate. Shu covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Alnylam Pharma, and Cue Biopharma.
Black Diamond Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $51.50, which is a 106.2% upside from current levels. In a report issued on January 18, Canaccord Genuity also maintained a Buy rating on the stock with a $50.00 price target.
See today’s analyst top recommended stocks >>
Sesen Bio (SESN)
Canaccord Genuity analyst John Newman maintained a Buy rating on Sesen Bio yesterday and set a price target of $5.00. The company’s shares closed last Monday at $1.75, close to its 52-week high of $2.00.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 30.4% and a 49.9% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Allogene Therapeutics, and Atara Biotherapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sesen Bio with a $3.63 average price target.
Johnson & Johnson (JNJ)
Argus Research analyst David Toung reiterated a Buy rating on Johnson & Johnson on January 28 and set a price target of $180.00. The company’s shares closed last Monday at $162.71.
According to TipRanks.com, Toung is a 4-star analyst with an average return of 11.4% and a 70.4% success rate. Toung covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, AmerisourceBergen, and Novartis.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Johnson & Johnson with a $188.67 average price target, implying a 14.1% upside from current levels. In a report issued on January 26, Raymond James also assigned a Buy rating to the stock with a $183.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on JNJ:
